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Abstract 
Background Pharmacological modulation of metabotropic glutamate receptor 5 (mGluR5) is of marked 
interest as a novel therapeutic mechanism to treat schizophrenia and major depression. However, the 
status of mGluR5 in the pathophysiology of these disorders remains unknown. Discussion The majority of 
studies in the schizophrenia post-mortem brain indicate that total mGluR5 expression is unaltered. 
However, close examination of the literature suggests that these findings are superficial, and in actuality, 
a number of critical factors have not yet been considered; alterations may be highly dependent on brain 
region, neuronal population or molecular organisation in specific cellular compartments. A number of 
genetic knockout studies (mGluR5, Norbin, Homer1 etc.) continue to lend support to a role of mGluR5 in 
the pathology of schizophrenia, providing impetus to explore the regulation of mGluR5 beyond total 
mGluR5 protein and mRNA levels. With regards to major depression, preliminary evidence to date shows 
a reduction in total mGluR5 protein and mRNA levels; however, as in schizophrenia, there are no studies 
examining mGluR5 function or regulation in the pathological state. A comprehensive understanding of 
mGluR5 regulation in major depression, particularly in comparison to schizophrenia, is crucial as this has 
extensive implications for mGluR5 targeting novel therapeutics, especially considering that opposing 
modulation of mGluR5 is of therapeutic interest for these two disorders. Summary Despite the 
complexities, examinations of post-mortem human brain provide valuable insights into the pathologies of 
these inherently human disorders. It is important, especially with regards to the identification of novel 
therapeutic drug targets, to have an in depth understanding of the pathophysiologies of these disorders. 
We posit that brain region- and cell type-specific alterations exist in mGluR5 in schizophrenia and 
depression, with evidence pointing towards altered regulation of this receptor in psychiatric pathology. We 
consider the implications of these alterations, as well as the distinction between schizophrenia and 
depression, in the context of novel mGluR5 based therapeutics. 
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Rethinking metabotropic glutamate receptor 5
pathological findings in psychiatric disorders:
implications for the future of novel therapeutics
Kelly A Newell1,2* and Natalie Matosin1,2
Abstract
Background: Pharmacological modulation of metabotropic glutamate receptor 5 (mGluR5) is of marked interest as
a novel therapeutic mechanism to treat schizophrenia and major depression. However, the status of mGluR5 in the
pathophysiology of these disorders remains unknown.
Discussion: The majority of studies in the schizophrenia post-mortem brain indicate that total mGluR5 expression
is unaltered. However, close examination of the literature suggests that these findings are superficial, and in
actuality, a number of critical factors have not yet been considered; alterations may be highly dependent on brain
region, neuronal population or molecular organisation in specific cellular compartments. A number of genetic
knockout studies (mGluR5, Norbin, Homer1 etc.) continue to lend support to a role of mGluR5 in the pathology of
schizophrenia, providing impetus to explore the regulation of mGluR5 beyond total mGluR5 protein and mRNA
levels. With regards to major depression, preliminary evidence to date shows a reduction in total mGluR5 protein
and mRNA levels; however, as in schizophrenia, there are no studies examining mGluR5 function or regulation in
the pathological state. A comprehensive understanding of mGluR5 regulation in major depression, particularly in
comparison to schizophrenia, is crucial as this has extensive implications for mGluR5 targeting novel therapeutics,
especially considering that opposing modulation of mGluR5 is of therapeutic interest for these two disorders.
Summary: Despite the complexities, examinations of post-mortem human brain provide valuable insights into the
pathologies of these inherently human disorders. It is important, especially with regards to the identification of novel
therapeutic drug targets, to have an in depth understanding of the pathophysiologies of these disorders. We posit that
brain region- and cell type-specific alterations exist in mGluR5 in schizophrenia and depression, with evidence pointing
towards altered regulation of this receptor in psychiatric pathology. We consider the implications of these alterations, as
well as the distinction between schizophrenia and depression, in the context of novel mGluR5 based therapeutics.
Keywords: Metabotropic glutamate receptor, mGlu, mGluR5, GRM, Schizophrenia, Depression, Post-mortem human
brain, Novel antipsychotic, Novel antidepressant, Glutamate
Background
Metabotropic glutamate receptor subtype 5 (mGluR5) is an
exciting novel drug target for the treatment of psychiatric
disorders including schizophrenia and major depression
[1,2]. While the monoaminergic systems (e.g. dopamine,
serotonin, norepinephrine) are the main therapeutic targets
of current drugs used to treat schizophrenia and major de-
pression, evidence suggests that the glutamatergic system
and the N-methyl-D-aspartate receptor (NMDAR) in par-
ticular, play a key role in the underlying pathophysiology of
these disorders, at least in a subset of patients [3-6]. Target-
ing the glutamatergic NMDAR is therefore considered a
novel treatment strategy for these disorders. Accordingly,
NMDAR agonists such as d-serine show therapeutic poten-
tial for the treatment of schizophrenia [7], whilst the
NMDAR antagonist ketamine shows rapid antidepressant
effects in patients with treatment-resistant depression [8,9].
In both cases however, NMDAR-targeting drugs are
* Correspondence: knewell@uow.edu.au
1Centre for Translational Neuroscience, Faculty of Science, Medicine and
Health and Illawarra Health and Medical Research Institute, University of
Wollongong, Wollongong, NSW 2522, Australia
2Schizophrenia Research Institute, Darlinghurst, NSW 2010, Australia
© 2014 Newell and Matosin; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Newell and Matosin BMC Psychiatry 2014, 14:23
http://www.biomedcentral.com/1471-244X/14/23
confounded, specifically by high dose requirements and the
associated risk of excitotoxicity in the case of agonists [7],
and psychotomimetic effects, addictive properties and cog-
nitive decline in the case of antagonists [10-13]. As a result
of these confounds, the metabotropic glutamate receptors
have been identified as a possible avenue to regulate gluta-
matergic transmission, while minimising the unwanted ef-
fects of targeting the NMDAR directly [2,14]. mGluR5 is of
particular interest as it shares a structural and functional
link with the NMDAR, but unlike the NMDAR it is local-
ised in more selective brain regions where it fine-tunes glu-
tamatergic transmission [1].
mGluR5 positive allosteric modulators (PAMs) upregu-
late NMDAR function [15], whilst mGluR5 antagonists
and negative allosteric modulators (NAMs) downregulate
NMDAR activity [16]. These agents therefore have the po-
tential to treat NMDAR hypofunction and hyperfunction
states associated with schizophrenia and major depression
respectively. In spite of this exciting possibility, the success
of novel mGluR5-based therapeutics is dependent on the
status of mGluR5 in these disorders. Conflicting data be-
tween human pathophysiological studies, genetic studies
and animal studies make it unclear whether mGluR5 is in-
deed altered in these pathologies and what implications
this has for novel mGluR5 based therapeutics.
Discussion
Neuropathological findings and considerations
Protein studies
Post-mortem analyses of human brain tissue from psychi-
atric patients provide valuable insight into the potential
pathophysiology of these disorders. Often however, find-
ings in post-mortem human brain are inconsistent with
findings in more mechanistic studies such as animal- and/
or cell- based studies, highlighting the complexities of
these psychopathologies. We have recently reviewed the lit-
erature with regards to examination of mGluR5 in schizo-
phrenia [1]. Three out of four studies examining mGluR5
protein in post-mortem brain samples from schizophrenia
subjects (number of subjects ranging from 9 to 37) identi-
fied no change in mGluR5 protein (monomer) levels in the
prefrontal cortex (PFC), specifically Brodmann’s areas (BA)
9, 10, 11, 32 and 46 as well as the caudate, putamen and
nucleus accumbens [17-19]. In contrast to these findings,
Fatemi and colleagues [20] recently reported a large reduc-
tion in mGluR5 protein (monomer) levels in the PFC
(BA9) and lateral cerebellum of subjects with schizophre-
nia compared to controls (n = 15-20). Collectively, these
findings raise the strong probability that alterations to
mGluR5 in schizophrenia are brain region-specific and
possibly cohort specific. This reinforces the importance of
replication of findings in adjacent brain regions and inde-
pendent cohorts and raises the notion that it is likely that
mGluR5-based therapeutics will mediate region-specific ef-
fects as well as individual-specific effects depending on the
underlying neuropathology.
In major depression, mGluR5 monomer protein
levels have been reported to be reduced in the lateral
cerebellum [20] and prefrontal cortex (BA10) [21]
using two different cohorts (n = 15). While this might
suggest less heterogeneity of changes in this disorder,
the findings should be deemed as preliminary until
additional brain regions are examined and findings fur-
ther replicated in independent cohorts. An important
way forward for both schizophrenia and major depres-
sion will be to identify these cohort specific changes in
mGluR5, as well as other markers, in living patients.
The detection of peripheral biomarkers, such as single-
nucleotide polymorphisms, that have associations with
symptoms and brain pathology (for example, see
[5,22]), may pave the way for an individualised treat-
ment approach.
A fundamental issue confounding the interpretation
of these aforementioned immunoblot studies is that the
majority have focused on mGluR5 in the monomer form.
Mature functional mGluR5s exist in a disulphide-linked
dimer complex [23,24] and can only be activated by ago-
nists when in this dimer form [23]. Thus, alterations in
monomers alone may not have functional significance.
While one study reported no change in mGluR5 dimer
levels in the PFC (BA9) and lateral cerebellum in schizo-
phrenia and major depression [20], the use of reducing
conditions (5% β-mercaptoethanol, which breaks disul-
phide links) would have interfered with the dimerized sta-
tus of mGluR5. It is therefore unlikely that total dimers
were indeed measured and rather these measures were an
artefact of the experimental procedure, whereby the ratio
of monomers and dimers is reflective of the amount of re-
ducing agent used rather than a physiological indication.
There are no reported investigations of mGluR5 dimer
measures in non-reducing conditions in schizophrenia or
depression, however altered dimerization of another
mGluR, mGluR3, has been found in the PFC of schizo-
phrenia subjects [25]. It is crucial to take these experimen-
tal variables into account for future mGluR5 immunoblot
studies, and to determine whether dimer assembly is dis-
rupted in these neuropathologies, as this would render
mGluR5 present, but inactive, thereby having implica-
tions for the novel class of mGluR5-targeting therapeutics.
While mGluR5 monomers are considered non-functional
as they cannot be activated by agonists, a recent report
suggests that mGluR5 monomers are able to couple to
G-proteins upon activation with a PAM [23]. However
more research is required to determine if mGluR5 di-
mers are altered in these psychiatric pathologies and
what impact this has on the effectiveness of mGluR5
allosteric agents [26].
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Receptor binding studies
Another valuable approach to understanding mGluR5 in
psychiatric pathology and its potential as a therapeutic tar-
get is the use of radiolabeled drugs that target the thera-
peutic binding site of interest. We have recently reported
no change in binding to the MPEP site of mGluR5 in the
post-mortem dorsolateral PFC of schizophrenia patients
[17]. We have also since found unaltered mGluR5 binding
in the anterior cingulate cortex of schizophrenia, major
depression and bipolar subjects in the Stanley Neuropath-
ology Consortium (unpublished observations). Consider-
ing many novel mGluR5 drugs target the MPEP site, our
findings suggest that this binding site is accessible in these
disorders, at least in the dorsolateral PFC and anterior cin-
gulate cortex. While these are the only studies to have ex-
amined mGluR5 binding in schizophrenia, Deschwanden
et al. [21] reported region-specific reductions in [11C]
ABP688 in-vivo binding to the MPEP site in the PFC, in-
sula, and parts of the parietal and temporal cortices in liv-
ing patients with depression. These alterations were
associated with depressive symptom severity. Considering
Deschwanden and colleagues also reported reductions in
mGluR5 protein in the PFC in major depression (in a sep-
arate post-mortem cohort) [21], it is possible that these re-
ductions in binding and protein represent a reduction in
overall mGluR5 numbers in the PFC in depression. Not-
ably, in line with our observations, no significant change
in binding was reported in the anterior cingulate cortex
[21]. The assessment of binding specifically to membrane
bound mGluR5 and the affinity of novel mGluR5 targeting
drugs to binding sites in the brains of patients with schizo-
phrenia and depression will aid in understanding the po-
tential of these drugs for the treatment of psychiatric
disorders. While assessment of the MPEP binding site of-
fers insight into the binding kinetics of mGluR5 drugs that
target this site, it must be noted that there is a family of
mGluR5 allosteric modulators that do not bind to this site
[27-29], and currently there are no radioligands available
to directly assess the density and affinity of these non-
MPEP sites.
mRNA studies
Although mRNA analyses do not directly equate to func-
tional protein expression [30], examination of mRNA of-
fers several advantages. Firstly, it allows for analyses of
amino acid sequences that are highly specific to the mol-
ecule or isoform of interest. Secondly, to gain an under-
standing of underlying mechanisms of any changes in
protein expression (for example whether they may be the
result of changes in rate of synthesis), examination of
mRNA expression is essential. Most recently, it was re-
ported that there was no change in mGluR5(pan) mRNA
in the PFC(BA9), together with a reduction in mGluR5
(pan) mRNA in the lateral cerebellum in schizophrenia
[20]. This same study found reduced mGluR5 protein in
both the cerebellum and PFC, indicating possible defi-
cits in mGluR5 synthesis in the cerebellum, but post-
transcriptional modifications in the PFC. Consistent with
this, four previous studies found no change in mGluR5
mRNA in the PFC (BA9/10), as well as the thalamus or
hippocampus in schizophrenia [31-34]. One study did how-
ever report an increase in mGluR5 mRNA expression in
the PFC (BA11; n = 7-10), which was specific to cortical
layer III [34], a layer concerned with cortico-cortical projec-
tions and that is particularly implicated in schizophrenia
pathophysiology [35]. It should therefore be considered that
alterations in mGluR5 mRNA are not only brain region-
specific, but may also exist specifically in selective neuronal
populations in the diseased brain, and analyses of total
neuron populations may therefore conceal pathological al-
terations. With regards to major depression, preliminary
studies suggest concordant reductions in mRNA and pro-
tein in post-mortem brain samples. Fatemi et al. [20] re-
cently reported a reduction in mGluR5(pan) mRNA in the
lateral cerebellum in major depression, consistent with their
finding of reduced mGluR5 protein in this same region.
This suggests that a reduction in mGluR5 production may
occur, at least in this brain region, in major depression. To
our knowledge, there are no other studies examining
mGluR5 mRNA in major depression to shed light on the
mechanism and extent of mGluR5 alterations in this
disorder.
Further considerations
When approaching mGluR5 post-mortem findings in the
context of future therapies, there has been minimal consid-
eration of the structural complexity of this receptor. To
date, mGluR5a, b, and d isoforms have been identified.
These isoforms differ in their developmental profile, brain
region localisation, and length of their c-terminus [1,36,37].
While mGluR5a and mGluR5b share similar pharmaco-
logical profiles they have opposing functions, at least in
development, where mGluR5a inhibits and mGluR5b pro-
motes neurite outgrowth [37]. Compared to mGluR5a and
b, the mGluR5d isoform has increased sensitivity to desen-
sitisation and has a shorter intracellular c-terminus by a sig-
nificant 267 amino acids [36]; consequently mGluR5d has
less interaction with scaffolding molecules that modulate
the mGluR5/NMDAR complex (e.g. Homer), and other en-
dogenous molecules that ensure its trafficking and cell sur-
face localisation. This is important to consider, especially in
the context of schizophrenia where the majority of studies
indicate no change in overall mGluR5 levels; there may
in reality be altered regulation, trafficking or recycling of
mGluR5 or altered receptor-receptor interactions. For
example, Homer, Norbin (neurochondrin) and Tamalin
(GRASP1) act as chaperones to increase cell surface local-
isation of mGluR5. Homer and Norbin knockout mice
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show a schizophrenia-like behavioural phenotype [38,39],
suggesting there may be deficits in membrane-bound local-
isation of mGluR5 in schizophrenia. Supporting this hy-
pothesis, the mGluR5 GRM5 gene has recently been
suggested as one of the top candidate genes for schizophre-
nia vulnerability [40,41], with exome sequencing of multi-
plex pedigrees reporting disruption to the mGluR5/Tamalin
association [40]. Consistent with this notion, mGluR5
knockout mice and mice treated with mGluR5 antago-
nists also demonstrate schizophrenia-like behaviours
(and interestingly antidepressant behaviours, as dis-
cussed below) [1,42]. While these mGluR5 regulatory
molecules have not been considered in the context of
depression, Homer1 has been implicated in the aetiology
of major depression through a genome wide association
study [43], suggesting possible disruptions to mGluR5
trafficking and/or mGluR5/NMDAR interactions in this
disorder also.
Opposing glutamatergic dysregulation in schizophrenia
and depression: Implications for novel mGluR5 therapeutics
mGluR5 PAMs have shown promise in preclinical rodent
models for the treatment of schizophrenia [1]. mGluR5
PAMs, such as CDPPB and more recently VU0364289,
demonstrated the ability to attenuate phencyclidine and
amphetamine-induced hyperlocomotion, social interaction
deficits, prepulse inhibition deficits and importantly, cog-
nitive deficits (which are largely untreated by current anti-
psychotics) [1,44]. While the development of mGluR5
PAMs have faced issues with regards to solubility and oral
bioavailability, a new generation of PAMs appear to have
overcome these issues [45-47]. In contrast, mGluR5
NAMs, including MPEP and MTEP, have shown anti-
depressant properties in rodent models, including reduced
immobility time in forced swim and tail suspension tests,
key tests of antidepressant efficacy in rodent models
[48-50]. However, some mGluR5 NAMs have also shown
the ability to produce psychotomimetic side effects in ro-
dent models, similar to the NMDAR antagonist ketamine
[51]. More recent drug design has resulted in the develop-
ment of mGluR5 NAMs that appear to lack this psychoto-
mimetic property [47].
While the glutamatergic system is implicated in the
pathophysiologies of both schizophrenia and major de-
pression, the use of mGluR5 PAMs for the treatment of
schizophrenia and NAMs for the treatment of depression,
suggests opposing disturbances of the glutamatergic sys-
tem in these disorders. Although the data for mGluR5 in
the schizophrenia brain is conflicting across studies [1,20]
(possibly as a result of region-specific pathology), a decline
in mGluR5 in depression has now been replicated in three
cohorts [20,21]. However, negative modulation of mGluR5
has been reported to have therapeutic efficacy in preclin-
ical (rodent) models of depression [9,52]. In addition,
NMDAR antagonists, such as ketamine, demonstrate anti-
depressant properties in treatment resistant patients [10].
From the outset, the use of these therapies might indicate
a hyperglutamatergic state or specific NMDAR hyperfunc-
tion in depression, suggesting that the mGluR5 reduction
seen in patients with depression represents an endogenous
compensatory response, and that the use of mGluR5
NAMs may act to further assist this mGluR5 downregula-
tion. This is supported by findings of increased glutamate
levels in the brains of some patients with depression
[4,53-55]. As the results of clinical trials for mGluR5
NAMs in depression are not yet available, the therapeutic
effects remain to be seen. It is likely that the incorporation
of mGluR5-based therapeutics will be individualized de-
pending on symptom profile and individual pathology.
The issues raised here are not limited to schizophrenia
and major depression. Glutamatergic dysfunction is also
implicated in other neuropsychiatric disorders including
anxiety and Fragile X Syndrome. mGluR5 NAMs prevent
behavioural phenotypes in animal models of these disor-
ders [56-58]. mGluR5 NAMs including Fenobam and
AFQ056 have progressed to clinical trials where they
showed therapeutic effects for the treatment of anxiety
and Fragile X Syndrome [59-61]. However there were re-
ports of psychotomimetic effects following chronic treat-
ment in some patients [59]. In addition, a recent study
provides evidence that patient response to these mGluR5
NAMs may depend on individual pathophysiology [61].
This demonstrates, despite some limitations which are be-
ing considered in current drug design [62], that this class
of drugs has the potential to progress into clinical thera-
peutics. mGluR5 PAMs on the other hand are yet to reach
clinical trials.
Summary
We suggest that, despite post-mortem studies largely
indicating no involvement of mGluR5 in the pathology
of schizophrenia, and preliminary evidence suggesting
it is down-regulated in major depression, that there is
evidence in both pathologies of altered regulation of
this receptor, possibly in a brain region- and cell type-
specific manner. In spite of the rapid movement to de-
velop mGluR5 pharmaceutical modulators, there has
been very limited investigation into the function and
regulation of mGluR5 at the genetic, mRNA and pro-
tein levels in the pathological post-mortem human and
animal paradigms [63]. Only with this knowledge will
we be able to tailor novel therapeutics to treat these
diseases. It is likely that mGluR5-based therapeutics
will be much individualised depending on symptom
profile. Pharmacogenomics or peripheral biomarkers
may help to identify the patients that would suit
mGluR5-modulation as a therapy option.
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